tirzepatide patient assistance program eli lilly China Clears Lilly's Weight Loss Drug Tirzepatide, Only For Diabetes Eli Lilly gets nod to

doi: 10.1177/20420188221127142 38 HuYDingBShenYYanRNLiFFSunRet al

approval 2022) and Zepbound (FDA-approved 8 November 2023)

The main results of the trial were as follows: Patients taking the maximum dose (12mg) lost an average of 70.3 lbs (28.3%) over 80 weeks Participants with a baseline body mass index (BMI) of 35 or above lost an average of 85 lbs (30.3%) over 104 weeks 45.3% of patients taking the maximum 12 mg dose lost 30% or more of their starting body weight a result normally seen after weight loss (bariatric) surgery The study also found significant improvements in key markers for metabolic syndrome, such as waist circumference, blood pressure, and harmful blood fats such as triglycerides and non-HDL cholesterol How does retatrutide compare to other weight loss medications

Very limited clinical data

The right digestive aids can mean the difference between comfortable, efficient digestion and hours of bloating and discomfort after meals